TCIM
PRQR icon

TIAA CREF Investment Management’s ProQR Therapeutics PRQR Stock Holding History

TIAA CREF Investment Management’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$1.56M Buy
112,228
+95,806
+583% +$1.43M ﹤0.01% 2122
2018
Q4 		$259K Buy
+16,422
New +$301K ﹤0.01% 2815

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

TIAA CREF Investment Management's PRQR Position: Q1 2019 in Review

TIAA CREF Investment Management increased its ProQR Therapeutics (PRQR) stake by 583% in Q1 2019, buying an estimated $1.43M and bringing the position to 112,228 shares worth $1.56M. The position accounts for ﹤0.01% of the portfolio, ranked #2122.

TIAA CREF Investment Management first reported a position in PRQR in Q4 2018 and has held it in 2 quarters since. 56 funds tracked by Wall St. Rank hold PRQR as of Q1 2019.

  • TIAA CREF Investment Management held 112,228 shares of ProQR Therapeutics worth $1.56M as of Q1 2019.
  • TIAA CREF Investment Management bought 95,806 ProQR Therapeutics shares in Q1 2019, an estimated $1.43M.
  • ProQR Therapeutics made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2122 holding.
  • TIAA CREF Investment Management first reported a position in ProQR Therapeutics in Q4 2018 and has held it in 2 quarters since.
  • 56 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.